Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
Jie Li(Hebei General Hospital), Liying Xue(Hebei Medical University)
Cited by 18
Related Papers
Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells
|Molecular Medicine Reports|2021|18